| Website | supergen.com |
| Category | BioTech |
| Phone | 925-560-0100 |
| Employees | 85 |
| Founded | 1991 |
| Description | pharmaceutical company |
| Astex, 4/11 | $55M |
SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. Products in Development MP-470—DNA Repair Suppressor: MP-470 is a multi-targeted Tyrosine Kinase Inhibitor that is specific for mutant forms of c-kit, PDGFRa, and FLT3. These protein kinase targets are involved in the growth and proliferation of cancer cells. MP-470 is also a suppressor of Rad51, a DNA repair protein which is involved in resistance to various chemotherapy agents and radiation.
SuperGen, Inc. was founded in 1991.
